SYSTEMIC PRODUCTION OF VISFATIN IN WOMEN WITH KNEE OSTEOARTHRITIS

  • Г. А. Игнатенко FSBEI HE «M. Gorky Donetsk State Medical University» MOH Russia, Donetsk
  • П. Н. Федуличев S.I. Georgievsky Medical Institute of Vernadsky CFU, Simferopol
  • Н. А. Резниченко S.I. Georgievsky Medical Institute of Vernadsky CFU, Simferopol

Abstract

Objective. To study serum concentrations of visfatin in postmenopausal women with gonarthritis. Materials and methods. 439 postmenopausal women were examined. Of these, 169 people with knee osteoarthritis were included in the main group. The remaining 270 women without signs of joint disease formed the control group. Results. A significant increase in systemic production of visfatin was found in postmenopausal women with knee osteoarthritis (p<0.001). In addition, positive correlations were found for visfatin values with body mass index, concentrations of TNF-α and IL-6 in the general group of women, as well as with the Kellgren-Lawrence radiological stage of osteoarthritis and functional joint failure among women with gonarthritis (p<0.05). Conclusion. The data obtained indicate a direct connection between the systemic production of visfatin and body mass index, the development of gonarthritis, its progression, and the main proinflammatory cytokines. It is advisable to use the results obtained for further research and take them into account when providing specialized medical care to postmenopausal women with knee osteoarthritis.

References

1. Michael J.W., Schlüter-Brust K.U., Eysel P. The epidemiology, etiology, diagnosis, and treatment of osteoarthritis of the knee. Dtsch Arztebl Int. 2010; 107 (9): 152-162. doi: 10.3238/arztebl.2010.0152
2. World Health Organization Disease incidence, prevalence and disability. Glob. Burd. Dis. 2004; 3: 28-37.
3. Федуличев П.Н. Традиционные факторы риска развития остеоартрита (обзор литературы). Медико-социальные проблемы семьи. 2022; (4): 117-124.
4. Федуличев П.Н. Современные представления о генетике остеоартрита. Крымский журнал экспериментальной и клинической медицины. 2023; 13 (1): 58-67.
5. O’Neill T.W., McCabe P.S., McBeth J. Update on the epidemiology, risk factors and disease outcomes of osteoarthritis. Best Practice & Research in Clinical Rheumatology. 2018; 32: 312-326. doi: 10.1016/j.berh.2018.10.007
6. Berenbaum F. Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage. 2013; 21 (1): 16-21. doi: 10.1016/j.joca.2012.11.012.
7. Liu S., Deng Z., Chen K. et al.. Cartilage tissue engineering: From proinflammatory and anti‑inflammatory cytokines to osteoarthritis treatments (Review). Mol Med Rep. 2022; 25 (3): 99. doi: 10.3892/mmr.2022.12615.
8. Seow S.R., Mat S., Ahmad Azam A. et al. Impact of diabetes mellitus on osteoarthritis: a scoping review on biomarkers. Expert Rev Mol Med. 2024; 26: e8. doi: 10.1017/erm.2024.7.
9. Dakroub A., A.Nasser S., Younis N. et al.. Visfatin: A Possible Role in Cardiovasculo-Metabolic Disorders. Cells. 2020; 9 (11): 2444. doi: 10.3390/cells9112444.
10. Franco-Trepat E., Guillán-Fresco M., Alonso-Pérez A. et al.. Visfatin Connection: Present and Future in Osteoarthritis and Osteoporosis. J Clin Med. 2019; 8 (8): 1178. doi: 10.3390/jcm8081178.
11. Игнатенко Г.А., Ластков Д.О., Дубовая А.В. и др.. Влияние загрязнения окружающей среды на состояние здоровья населения: взаимосвязь дисэлементоза с различной патологией сердечно-сосудистой системы: монография. Забайкальский государственный университет. Чита: ЗабГУ, 2021. 231 с.
12. Игнатенко Г.А., Мухин И.В., Ляшенко Е.Г и др.. Качество жизни больных хронической обструктивной болезнью легких, ассоциированной с дислипидемией. Вестник гигиены и эпидемиологии. 2021; 25 (1): 5-9.
13. Поворознюк В.В., Резниченко Н.А., Майлян Э.А. Роль иммунных факторов в патогенезе постменопаузального остеопороза. Проблемы остеологии. 2013; 16 (3): 3-7.
14. Майлян Э.А. Современные представления об этиологии и патогенезе постменопаузального остеопороза. Проблемы остеологи. 2015; 18 (2): 3-11.
15. Майлян Э.А., Игнатенко Г.А., Резниченко Н.А. Риск постменопаузального остеопороза и уровни цитокинов в зависимости от полиморфизма rs2234693 гена ESR1. Забайкальский медицинский вестник. 2018; (1): 45-51.
16. Майлян Э.А., Игнатенко Г.А., Резниченко Н.А.Уровни гормонов и маркеров костного обмена при постменопаузальном остеопорозе. Медико-социальные проблемы семьи. 2018; (1): 41-48.
17. Майлян Э.А., Резниченко Н.А., Игнатенко Г.А. Сывороточные уровни цитокинов при постменопаузальном остеопорозе. Крымский журнал экспериментальной и клинической медицины. 2018; 8 (1): 36-42.
18. Agbaedeng T.A., Iroga P.E., Rathnasekara V.M., Zacharia A.L. Adipokines and stroke: A systematic review and meta-analysis of disease risk and patient outcomes. Obes Rev. 2024; 25 (4): e13684. doi: 10.1111/obr.13684.
19. Deepika F., Bathina S., Armamento-Villareal R. Novel Adipokines and Their Role in Bone Metabolism: A Narrative Review. Biomedicines. 2023; 11 (2): 644. doi: 10.3390/biomedicines11020644.
20. Kärberg K., Forbes A., Lember M. Unlocking the Dietary Puzzle: How Macronutrient Intake Shapes the Relationship between Visfatin and Atherosclerosis in Type 2 Diabetes. Medicina (Kaunas). 2024; 60 (3): 438. doi: 10.3390/medicina60030438.
21. Varra F.N., Varras M., Varra V.K., Theodosis-Nobelos P. Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review). Mol Med Rep. 2024; 29 (6): 95. doi: 10.3892/mmr.2024.13219.
22. Askari A., Arasteh P., Homayounfar R. et al.. The role of adipose tissue secretion in the creation and pain level in osteoarthritis. Endocr Regul (2020) 54 (1): 6–13. doi: 10.2478/enr-2020-0002
23. Bas S., Finckh A., Puskas G.J. et al.. Adipokines correlate with pain in lower limb osteoarthritis: different associations in hip and knee. Int Orthop. 2014; 38 (12): 2577-83. doi: 10.1007/s00264-014-2416-9.
24. Chen W.P., Bao J.P., Feng J. et al.. Increased serum concentrations of visfatin and its production by different joint tissues in patients with osteoarthritis. Clin Chem Lab Med. 2010; 48 (8): 1141–5. doi: 10.1515/CCLM.2010.230
25. Fioravanti A., Cheleschi S., De Palma A. et al.. Can adipokines serum levels be used as biomarkers of hand osteoarthritis? Biomarkers. 2018; 23 (3): 265–70. doi: 10.1080/1354750X.2017.1401665
26. Hülser M.L., Luo Y., Frommer K. et al.. Systemic versus local adipokine expression differs in a combined obesity and osteoarthritis mouse model. Sci Rep. 2021; 11 (1): 17001. doi: 10.1038/s41598-021-96545-8.
27. Tsai C.H., Liu S.C., Chung W.H. et al.. Visfatin Increases VEGF-dependent Angiogenesis of Endothelial Progenitor Cells during Osteoarthritis Progression. Cells. 2020; 9 (5): 1315. doi: 10.3390/cells9051315.
28. Klein-Wieringa I.R., Kloppenburg M., Bastiaansen-Jenniskens Y.M. et al.. The infrapatellar fat pad of patients with osteoarthritis has an inflammatory phenotype. Ann. Rheum. Dis. 2011; 70: 851-857. doi: 10.1136/ard.2010.140046.
29. Laiguillon M.-C., Houard X., Bougault C. et al.. Expression and function of visfatin (Nampt), an adipokine-enzyme involved in inflammatory pathways of osteoarthritis. Arthritis Res. Ther. 2014; 16: 38. doi: 10.1186/ar4467.
30. Шпаков А.О. Висфатин и его роль в регуляции репродуктивной системы. Трансляционная медицина. 2019; 6 (2): 25-36.
31. Poonpet T., Honsawek S. Adipokines: Biomarkers for osteoarthritis? World J Orthop. 2014; 5 (3): 319-27. doi: 10.5312/wjo.v5.i3.319.
Published
2024-07-01
How to Cite
ИГНАТЕНКО, Г. А.; ФЕДУЛИЧЕВ, П. Н.; РЕЗНИЧЕНКО, Н. А.. SYSTEMIC PRODUCTION OF VISFATIN IN WOMEN WITH KNEE OSTEOARTHRITIS. University Clinic, [S.l.], n. 2(51), p. 5-11, july 2024. ISSN 1819-0464. Available at: <http://journal.dnmu.ru/index.php/UC/article/view/2078>. Date accessed: 25 apr. 2025.
Section
Оригинальные исследования